SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kinetics in Patients With Renal Cell Carcinoma (RCC) and Urothelial Carcinoma (UC) Treated With Immune Checkpoint Blockade (ICB)

Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kinetics in Patients With Renal Cell Carcinoma (RCC) and Urothelial Carcinoma (UC) Treated With Immune Checkpoint Blockade (ICB)


  • Org Study ID: GU-118
  • Secondary ID:
  • NCT ID: NCT03291028
  • NCT Alias:
  • Sponsor: Fox Chase Cancer Center - Other
  • Source: Fox Chase Cancer Center

Brief Summary

This is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune checkpoint blockade (ICB) treatment targting programmed cell death 1 (PD1) but developed new lesions later were also removed and stored in the biosample repository (BSR). The histology and genomic analysis of the pre-treatment and metastatic samples from the same patient would be used to find out the changes that may have lead to metastasis. Also, metastatic samples from ICB naive patients would be collected and compared with those from ICB treated patients to find out if the metastasis in treated patients was due to development of reistance.

Overal Status Start Date Phase Study Type
Recruiting November 27, 2017 N/A Observational

Primary Outcomes:

Primary Outcome 1 - Measure: Histopathological characterization of samples from ICB treated patients

Primary Outcome 1 - Time Frame: 18 months

Primary Outcome 2 - Measure: Genomic characterization of samples from ICB treated patients

Primary Outcome 2 - Time Frame: 18 months

Condition:

  • Renal Cell Carcinoma
  • Urothelial Carcinoma
  • Bladder Cancer
  • Ureter Cancer
  • Urethral Cancer

Eligibility

Criteria:
Inclusion Criteria:

- Eligible patients will include retrospectively identified patients with RCC or UC who
have received treatment with ICB and achieved clinical benefit but subsequently
developed a solitary new/progressive lesion that was removed surgically. Patients with
other tumor types who otherwise meet criteria may be included at a later time

- Additionally, a group of patients with RCC who have undergone a metastasectomy but who
did not receive treatment with ICB will be identified. These patients may be
approached for study participation to serve as a comparator group

Exclusion Criteria:
Show More

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

Overall Contact

Name: Matthew Zibelman, MD

Phone: 215 214 1515

Email: matthew.zibelman@fccc.edu

Location

Facility Status Contact
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania 19111-2497
United States
Recruiting Elizabeth Plimack, MD
215-728-4790
Elizabeth.Plimack@fccc.edu